Ontology highlight
ABSTRACT:
SUBMITTER: Zhang T
PROVIDER: S-EPMC11324870 | biostudies-literature | 2024 Aug
REPOSITORIES: biostudies-literature
Zhang Tao T Pan Zilu Z Gao Jing J Wu Qingqing Q Bai Gang G Li Yan Y Tong Linjiang L Feng Fang F Lai Mengzhen M Liu Yingqiang Y Song Peiran P Ning Yi Y Tang Haotian H Luo Wen W Chen Yi Y Fang Yan Y Zhang Hui H Liu Qiupei Q Zhang Yudi Y Wang Hua H Chen Zhiwei Z Chen Yi Y Geng Meiyu M Ji Hongbin H Zhao Guilong G Zhou Hu H Ding Jian J Xie Hua H
Signal transduction and targeted therapy 20240815 1
Third-generation EGFR tyrosine kinase inhibitors (TKIs), exemplified by osimertinib, have demonstrated promising clinical efficacy in the treatment of non-small cell lung cancer (NSCLC). Our previous work has identified ASK120067 as a novel third-generation EGFR TKI with remarkable antitumor effects that has undergone New Drug Application (NDA) submission in China. Despite substantial progress, acquired resistance to EGFR-TKIs remains a significant challenge, impeding the long-term effectiveness ...[more]